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Introduction 
 Atherosclerosis is an extremely common disorder around the world, and has become a 
leading cause of death and disability (Kelley, 2011). Vascular disease is known to primarily 
affect older patients. However, a study by Kelley et al. has found that the prevalence of 
atherosclerotic plaques in young and middle-aged people has risen to 8-14% (Kelley, 2011). 
Atherosclerosis is also one of the most commonly misunderstood diseases by the common 
citizen. It is a common misconception that atherosclerosis is characterized simply by plaque 
formation in the vasculature due to poor diet or genetic disposition. It is actually an inflammatory 
disease (Rudijanto, 2007). 
Lesions on the vascular walls were previously thought to consist mostly of lipids; 
however, they are now known to contain cells, connective-tissue elements, lipids, and debris 
(Rudijanto, 2007). Atherosclerosis begins after initial injury to the endothelial lining of the 
vasculature. Injury can be caused by numerous conditions including diabetes mellitus, 
hypertension, dyslipidemia, and poor flow due to branching of the vasculature. Injured 
endothelial cells, along with platelets, release growth factors and cytokines. These molecules can 
promote vascular smooth muscle cells to change from their native contractile phenotype to a 
more active one – the synthetic, or proliferative, phenotype. VSMCs originally mature from the 
synthetic phenotype to contractile, which is the phenotype necessary for VSMCs to perform their 
normal functions. Hayashi posits that the exact cause of the phenotype switching remains 
unknown. However, research conducted has shown that molecules such as unsaturated 
lysophosphatidic acids can cause the modulation (Hayashi et al., 2001).  
Additionally, conditions such as hypoxia, along with endothelial injury, may cause the 
VSMCs to switch back to the synthetic phenotype. A study by Korshunov found that vascular 
remodeling in mice may even be caused by genetic determinants (Korshunov et al., 2004). This 
makes it even more imperative that an effective treatment be developed, as factors beyond 
behavior of the specimen play a large role in vascular disease. The synthetic VSMC phenotype 
can migrate and proliferate, which causes the formation of a lesion after mixing with areas of 
inflammation. Additionally, the synthetic VSMCs can synthesize molecules such as collagen and 
proteoglycans, which can pose further problems. (Rudijanto, 2007). 
Yi et al. and Wang et al. have studied the role of hypoxia and high glucose concentration 
in phenotype modulation. Through their studies, it has been shown that hypoxia plays a large 
role in VSMC proliferation through phenotype switching (Wang, 2010). However, avoiding 
these conditions altogether is not feasible, and reversing the damage caused by said problems is 
not simple. There are several pathways involved in phenotype modulation including PI3K-Akt, 
MLCK, and PKC, and targeting any single pathway does not reverse the phenotype modulation 
(Yi, 2012). Thus, researchers such as Yi et al. have decided to target an upstream regulatory 
pathway, cGMP-dependent protein kinase (PKG). PKG is involved in numerous areas of the 
vasculature including muscle relaxation, platelet formation, and cell division (Yi, 2012).  
A study by Lincoln et al. further examined the role of PKG in phenotype expression in 
VSMCs. They examined repetitively passaged VSMCs which initially did not express PKG, and 
found they these cells existed in the synthetic phenotype. However, after gene transfection with 
PKG-Iα, the cells exhibited higher levels of contractile phenotype markers including calponin 
and SM-α-actin. The cells also exhibited lower levels of synthetic phenotype markers 
osteopontin and thrombospondin, along with a more contractile morphology. Lincoln further 
found that exposure of Nitric Oxide to SMCs reduced phenotype expression; this suggests that 
NO also plays a role in phenotype modulation and vascular injury (Lincoln et al., 1998). 
Research by Gilotti et al. has also found that molecules such as heparin and atrial 
natriuretic peptide (ANP) induce positive changes in the vasculature (Gilotti, 2013). Often 
thought of as simply a blood thinner, the studies discussed above demonstrate that heparin has an 
important relationship with PKG in anti-proliferation in the vasculature. The goal of this research 
is therefore to investigate the exact relationship between heparin the vasculature, and to see 
whether its effects are similar to those of PKG. Heparin seems to be an important biomolecule in 
regards to vasculature therapeutics. However, heparin must be investigated carefully and with 
prudence, as over administering heparin to a patient would have negative effects, such as 
reducing blood-clotting effects to extreme levels. This makes further heparin research all the 
more important. There is a dire need for vascular disease therapeutics, and heparin, or treatments 
based on heparin’s mode of action, could prove to be effective. Heparin may have effects similar 
to PKG on VSMCs phenotype markers, and these experiments aim to illustrate those effects. 
Methods and Materials 
 
 To examine the effect of heparin on phenotype modulation, Western Blots were 
performed to compare protein levels between treatment groups. Western blots were ran 
according to standard protocol. A7r5 cloned rat smooth muscle cells, along with primary bovine 
VSMCs, were treated in the experiments. DMEM or MEM and 2.5% trypsin/EDTA was used for 
cell culture stages. The phenotype markers that were examined are calponin and SM-α-actin, and 
polyclonal rabbit and goat antibodies were used for the blots.  
 Various treatment groups were used to illustrate the effects of heparin on the VSMCs. 
Control group VSMCs were incubated under standard conditions for 24, 48, or 72 hours. The 
first experiment also had a set of cells incubated with heparin (to saturation) for 24, 48, or 72 
hours. These cells were harvested and run through a western blot, stained for the specific 
proteins, and developed. An experiment was also performed to illustrate the effects of adding 
more heparin after 24 and 48 hours – this was done to show whether the heparin is absorbed or 
degraded; adding more heparin would theoretically upregulate the phenotype markers even more 
after the specified timespan. Finally, these experiments were also run with primary cells, as they 
may respond differently to the treatments than cloned cells do. 
Results 
 Multiple sets of gels were completed to attempt to show maximal effects of heparin. 
 
Figure One, A7r5, SM-α-actin, From left to right: 24 Hours, 24 Hours w/ Heparin, 48 Hours, 48 
Hours w/ Heparin, 72 Hours, 72 Hours w/ Heparin  
 
 
Figure Two, A7r5, Calponin, From left to right: 24 Hours, 24 Hours w/ Heparin, 48 Hours, 48 
Hours w/ Heparin, 72 Hours, 72 Hours w/ Heparin  
The following two gels involved adding more heparin two the plates of cells after 24 and 
48 hours. The experimental group involving this change is marked with “C” below (i.e. 48C and 
72C). Groups where heparin was added only at time of cell splitting are marked with “H.” 
 
 
Figure Three, SM-α-actin, A7r5, 48, 48H, 48C, 72, 72H, 72C 
 
Figure four, Calponin, From left to right, A7r5, 48, 48H, 48C, 72, 72H, 72C 
The final gel run was stained for SM-α-actin and loaded with both primary (bovine VSMCs) and 
cloned (A7r5) cells. 
 
  
 
 
 
 
 
 
 
 
 
 
Figure five, SM-α-actin, From left to right, A7r5, A7r5 w/ Heparin, A7r5, A7r5 w/ Heparin 
(second set) Bovine VSMCs, Bovine VSMCs with Heparin 
Discussion 
 The first set of gels (Figures 1 & 2) seem to show upregulation of the phenotype markers 
at 24 hours. However, it is difficult to conclude definitively whether the darker protein regions 
on the gel are due to actual upregulation of the protein or due to loading differences in amount of 
cells between the lanes. ImageJ was used to attempt to discern whether the difference in band 
intensity was due to loading discrepancies, and the data showed that the difference between the 
lanes was not significant (i.e. that there were not major differences in loading amounts between 
the lanes). The results were inconclusive after further repeat experiments. There are several 
explanations behind this data: the heparin may have been degraded or absorbed by the cells after 
a specific time period, the heparin may not have an effect as initially hypothesized, or the 
specific cells used (A7r5) were not responding as hypothesized. To rule out the first explanation, 
the second set of gels was run. A group of cells were continually treated with heparin after 24 
and 48 hours to illustrate whether additional heparin would have any effect on the cells. Figures 
3 & 4 do not show any significant upregulation of the phenotype markers in the lanes treated 
with additional heparin. At this point, the hypothesis was that A7r5s, due to their highly synthetic 
nature, would not respond to heparin as primary cells would. Therefore, the third set of gels 
(Figure 5) were run with primary cells. However, the primary groups do not show significant 
differences in protein levels. The initial hypothesis may have been incorrect. Heparin may not 
induce powerful enough changes in cellular mechanisms to upregulate these phenotype markers 
and induce a switch back to the contractile phenotype. Further directions involve using heparin 
for a longer time period, trying different cell types, or examining different phenotype markers. 
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